Previous 10 | Next 10 |
Image source: The Motley Fool. Incyte Corporation (NASDAQ: INCY) Q2 2021 Earnings Call Aug 3, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Incyte Corporation (INCY) Q2 2021 Earnings Call Transcript
Incyte Corporation (INCY) Q2 2021 Earnings Conference Call August 03, 2021, 08:00 AM ET Company Participants Christine Chiou - Senior Director, Investor Relations Hervé Hoppenot - Chairman, President and Chief Executive Officer Barry Flannelly - Executive Vice President and General Manag...
The following slide deck was published by Incyte Corporation in conjunction with their 2021 Q2 earnings call. For further details see: Incyte Corporation 2021 Q2 - Results - Earnings Call Presentation
Incyte (NASDAQ:INCY) reports Q2 2021 results and provides an update on its development portfolio. Total revenues rose marginally by 2.6% to $705.7M, surpassing analyst estimates of $686.95M. Jakafi and Iclusig net product revenues rose 12% and 24%, respectively to $529.1M and $28.2M. Pemazyre...
Incyte (NASDAQ:INCY): Q2 Non-GAAP EPS of $0.80 beats by $0.06; GAAP EPS of $0.67 beats by $0.12. Revenue of $705.71M (+2.6% Y/Y) beats by $18.76M. Jakafi (ruxolitinib) revenues of $529M in Q2 2021 (+12% vs Q2 2020) FY21 Outlook: Jakafi (ruxolitinib) revenues of $2,125M - $2,170M from pri...
- Total product and royalty revenues of $696 million in Q2 2021 (+17% vs Q2 2020) - Jakafi ® (ruxolitinib) revenues of $529 million in Q2 2021 (+12% vs Q2 2020) - Positive CHMP opinion for tafasitamab in combination with lenalidomide for the treatment of a...
Eli Lilly (NYSE:LLY) and Incyte (NASDAQ:INCY) announce results from an additional cohort of 101 adult patients from the COV-BARRIER trial. In this sub-study, patients with COVID-19 on mechanical ventilation or extracorporeal membrane oxygenation (ECMO) who received baricitinib plus standard o...
Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation - New data from Phase 3 COV-BARRIER sub-study indicates one death prevented for every six baricitinib-treated patients on mechanical ventilation or ECMO compared ...
Calithera is guiding for the market to expect what we believe will be a key data read-out from its ongoing CB-280 study involving Cystic Fibrosis. We anticipate full data set to read out in early October at the North American Cystic Fibrosis Conference. A positive read-out here co...
Using the quarterly 13F filings, we extract 50 consensus stocks from 40 large hedge funds, each fund with more than $3.5 billion Assets Under Management. After the Q1-2021 13F filings, the consensus holdings are updated, 5 stocks were removed and 6 added from the universe; now holds 4...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 11:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 06:15:05 ET BMO Capital analyst issues UNDERPERFORM recommendation for INCY on July 2, 2024 04:26AM ET. The previous analyst recommendation was Market Perform. INCY was trading at $60.87 at issue of the analyst recommendation. The overall analyst consensus : B...